ASPHD1 (aspartate beta-hydroxylase domain containing 1) is a poorly characterized gene with emerging roles in disease pathogenesis and prognosis across multiple conditions. ASPHD1 was identified as a novel candidate causal gene for Lewy body dementia (LBD) through genome-wide association study and multi-omics integration, with enrichment in brain tissues including the dorsolateral prefrontal cortex and astrocytes 1. The gene participates in endoplasmic reticulum stress response pathways relevant to cancer progression; it was incorporated into prognostic risk models for both colon cancer and hepatocellular carcinoma, where elevated expression correlated with patient outcomes and immunotherapy response 23. In skin cutaneous melanoma, ASPHD1 upregulation was associated with longer overall survival and correlated with immune infiltration markers including CD4+/CD8+ T cells and checkpoint molecules CTLA4 and CD276, suggesting a role in tumor immune regulation 4. ASPHD1 has also been implicated in pain processing; differential DNA methylation at the ASPHD1 locus was identified in chr16 low back pain patients and associated with altered conditioned pain modulation 5. Additionally, ASPHD1 was upregulated as part of a host defense pathway against E. coli placental infection 6. ASPHD1 and the genetic variant rs925939730 were proposed as prognostic biomarkers in colorectal cancer 7. Overall, ASPHD1 appears to function in disease-relevant pathways affecting neurodegeneration, cancer progression, pain processing, and host-pathogen interactions, though its specific molecular mechanism remains to be elucidated.